Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 3/20 | 0.67 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.62 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.46 |
| ▸ | CASP2 | P42575 | 1/20 | 0.46 |
| ▸ | CES2 | O00748 | 3/20 | 0.46 |
| ▸ | CES1 | P23141 | 3/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19687365 | 0.84 | CASP2 (0.62) | CASP2EPHX2 | |
| SCHEMBL12636328 | 0.83 | PLA2G2A (0.79) | PLA2G2APLA2G4AEPHX1CASP2CES2 | |
| SCHEMBL17624918 | 0.82 | CASP2 (0.59) | CASP2EPHX2 | |
| SCHEMBL13991905 | 0.82 | TSHR (0.47) | PLA2G2AEPHX2 | |
| SCHEMBL4781039 | 0.78 | PLA2G4A (0.67) | PLA2G2APLA2G4ACES2CES1EPHX2 | |
| Monoethanolamine SCHEMBL6138913 | 0.78 | PLA2G2A (0.71) | PLA2G2APLA2G4AEPHX1CASP2CES2 | |
| Monoethanolamine SCHEMBL6139326 | 0.78 | PLA2G2A (0.71) | PLA2G2APLA2G4AEPHX1CASP2CES2 | |
| SCHEMBL15888712 | 0.77 | SMN1; SMN2 (0.60) | CASP2EPHX2 | |
| SCHEMBL17624903 | 0.77 | CASP2 (0.56) | CASP2EPHX2 | |
| SCHEMBL1877382 | 0.77 | PLA2G4A (1.00) | PLA2G2APLA2G4AEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |